An At-Home Cancer Test ToTheCenter.com, NY - Nov 28, 2008 However, colorectal cancer is often asymptomatic in the earliest stages and, therefore, not caught in time. In response to these statistics, ...
Recent research on cancer-fighting diets The Plain Dealer - cleveland.com, OH - Nov 25, 2008 The highest risk is for prostate, colorectal and breast cancer. Researchers at the University of California, San Diego School of Medicine have shown how ...
$6 Million Bets Ginseng Will Cure Colon Cancer HealthNews, CA - Nov 11, 2008 Their research center, called the Center for Herbal Research on Colorectal Cancer, will delve into ginseng?s anti-tumor effects through lab and animal ...
Breast Cancer Drug Avastin Meets Latest Study Goals HealthNews, CA - Nov 25, 2008 Avastin is also approved for use in advanced colorectal, lung and kidney cancer. To date, Avastin has been used to treat more than 350000 cancer patients. ...
Studies of DNA Methylation in Cancer Beginning to Yield Clinical ... Journal of American Medical Association (subscription), IL - Nov 11, 2008 In July, Laboratory Corporation of America Holdings began offering a noninvasive stool DNA test for colorectal cancer based on this research. ...
Source: Google News
Recent News and Articles on the Keywords: cancer + colorectal + aggressive Related to the article below (Last Update: 8/5/2008)
FDA Approves New Test for Aggressive Breast Cancer Enews 2.0, UK - Jul 9, 2008 Among men, the three most commonly diagnosed cancers are prostate, lung and colorectal cancer in developed countries and lung, stomach and liver cancer in ...
Let?s get personal Malaysia Star, Malaysia - Jul 26, 2008 Predictive biomarkers are useful not only in breast cancer. In colorectal cancer (cancer of the large intestine), we have the K-RAS oncogene. ...
Low Socioeconomic Status Increases Cancer Mortality Cancer Consultants, ID - Jul 24, 2008 Researchers from Emory University have recently reported that the declines in death rates from lung, breast, prostate, and colorectal cancer in persons ...
New cancer scanner at QEII TheChronicleHerald.ca, Canada - Jul 17, 2008 The PET/CT scanner isn?t meant to do the initial diagnosis of diseases like breast or colorectal cancer but can be used later to assess the effectiveness of ...
Belly up to better health - trim midsection fat The Desert Sun, CA - Jul 31, 2008 Last year, a panel of cancer experts concluded that there is convincing evidence that excess abdominal fat is a cause of colorectal cancer and probably a ...
Einstein Researchers ID Gene Pattern Linked to 5-FU Response in ... Pharmacogenomics Reporter (subscription), NY - Jul 16, 2008 By Turna Ray Scientists at the Albert Einstein College of Medicine of Yeshiva University have accurately predicted whether colorectal cancer tumors are ...
A Biotech Bloom in July Seeking Alpha, NY - Jul 28, 2008 Imclone?s (IMCL) cancer drug Erbitux received approval in Japan on July 16th for use in advanced colorectal cancer. With this approval, Eribtux is the first ...
Molecular detection (k-ras) of exfoliated tumour cells in the ... 7thSpace Interactive (press release), NY - Jul 27, 2008 ... by denaturing capillary electrophoresis with respect to mutations in hotspots of the k-ras gene, which are frequently mutated in colorectal cancer. ...
Initial Presentation With Stage IV Colorectal Cancer: How Aggressive Should We Be? - SA Rosen, JF Buell, A Yoshida, S Kazsuba, R Hurst, … - Archives of Surgery, 2000 - archsurg.highwire.org ... Initial Presentation With Stage IV ColorectalCancer How Aggressive Should
We Be? Seth A. Rosen, MD ; Joseph F. Buell, MD ; Atsushi ... -
Colorectal cancer screening: Clinical guidelines and rationale - SJ Winawer, RH Fletcher, L Miller, F Godlee, MH … - Gastroenterology, 1997 - Elsevier ... Adenomatous Polyposis tient deal with the high lifetime risk of colorectalcancer
and other cancers and the need for aggressive screening. Because ...
p53 point mutation and survival in colorectal cancer patients - HS Goh - Cancer Research, 1995 - AACR ... of the p53 tumor suppressor gene and survival in colorectalcancer patients ... domains
of the p53 tumor suppressor gene were inherently more aggressive than tumors ...
Aggressive Immune Response Helps Colorectal Cancer Patients
European researchers have discovered one of the reasons why some colorectal cancers are more aggressive and likely to spread than others.
The reason is that in some people, the body's immune system mounts an effective defense against the tumor and against the tumor's attempt to spread to other sites in the body.
The anti-tumor cells generated by the immune system are called "effector memory T cells."
"Effector memory T cells have the capacity to recognize and kill tumor cells. These cells, located in the tumor, have a long-lasting anti-tumor activity, persist within the body and destroy distant tumor cells," said one of the study's authors, Jerome Galon, a research scientist at the French National Institute of Health and Medical Research in Paris.
Results of the study appear in the Dec. 22 issue of the New England Journal of Medicine.
More than 140,000 new cases of colorectal cancer are diagnosed each year in the United States, according to the American Cancer Society (ACS). The disease is responsible for about 56,000 deaths each year, making it the nation's second-leading cause of cancer death, according to the ACS.
Because little is known about how the immune system responds when cancers begin to spread, Galon and his colleagues analyzed the immune response to colorectal cancer tumor samples from 959 people.
The researchers looked for evidence of early metastasis, or spreading, of the cancer. Early signs of metastasis include blood vessel blockages, invasion of the lymphatic system and infiltration of the nerves. Together, the researchers collectively referred to these signs as VELIPI. VELIPI-positive cancers were those that were already spreading to other sites throughout the body.
After identifying each tumor as VELIPI-positive (257) or VELIPI-negative (702), the researchers then compared the groups to see if there were any differences.
There were. People with VELIPI-negative tumors were more likely to have a higher density of effector memory T cells, and they were more likely to live longer. On average, those with VELIPI-negative tumors lived 35 months, compared to 16.3 months for those with VELIPI-positive tumors.
"Effector memory T cells have a major impact on colorectal cancer evolution. These cells prevent tumor dissemination within the body and distant metastasis, and improve survival of the patients," said Galon.
Galon said these T cells kill tumor cells that attempt to migrate from the original tumor.
"The immune system, under appropriate conditions, may be effective in controlling or limiting cancer spread if the appropriate number and quality of immune cells can be mobilized by the first tumor site," said Dr. Giorgio Parmiani, chairman of the unit of immunotherapy of human tumors and the department of innovative therapies at Istituto Nazionale Tumori in Milan, Italy. Parmiani wrote an accompanying editorial in the same issue of the journal.
Galon said these findings could eventually help classify and "stage" tumors, giving doctors a better way to predict the course a cancer might take. In the long-term, he added, these findings could help lead to the development of an immunotherapy that could boost the immune response, especially that of the effector memory T cells, to more effectively fight colorectal cancer.